[{"orgOrder":0,"company":"Creyon Bio","sponsor":"Cajal Neuroscience","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Neurology","graph2":"Discovery Platform","graph3":"Creyon Bio","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Creyon Bio \/ Cajal Neuroscience","highestDevelopmentStatusID":"3","companyTruncated":"Creyon Bio \/ Cajal Neuroscience"},{"orgOrder":0,"company":"Creyon Bio","sponsor":"DCVC Bio","pharmaFlowCategory":"D","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Oligonucleotide","year":"2022","type":"Series A Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Rare Diseases and Disorders","graph2":"Discovery Platform","graph3":"Creyon Bio","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Creyon Bio \/ DCVC Bio","highestDevelopmentStatusID":"3","companyTruncated":"Creyon Bio \/ DCVC Bio"},{"orgOrder":0,"company":"Creyon Bio","sponsor":"Eli Lilly","pharmaFlowCategory":"D","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Oligonucleotide","year":"2025","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Rare Diseases and Disorders","graph2":"Discovery Platform","graph3":"Creyon Bio","amount2":1.01,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Rare Diseases","amount2New":1.01,"dosageForm":"Undisclosed","sponsorNew":"Creyon Bio \/ Eli Lilly","highestDevelopmentStatusID":"3","companyTruncated":"Creyon Bio \/ Eli Lilly"}]

Find Clinical Drug Pipeline Developments & Deals by Creyon Bio

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          AAPS National Biotech
                          Not Confirmed
                          AAPS National Biotech
                          Not Confirmed

                          Details : Through the collaboration, Creyon will leverage its industry-first AI-Powered Oligo Engineering Engine to design and optimize new drug candidates for Lilly’s named targets.

                          Product Name : Undisclosed

                          Product Type : Oligonucleotide

                          Upfront Cash : $13.0 million

                          April 29, 2025

                          Lead Product(s) : Undisclosed

                          Therapeutic Area : Rare Diseases and Disorders

                          Highest Development Status : Discovery Platform

                          Sponsor : Eli Lilly

                          Deal Size : $1,013.0 million

                          Deal Type : Collaboration

                          blank

                          02

                          AAPS National Biotech
                          Not Confirmed
                          AAPS National Biotech
                          Not Confirmed

                          Details : Under the collaboration, the companies are developing antisense oligonucleotides (ASOs) leveraging the powerful Creyon™ Platform for multiple neurodegenerative diseases.

                          Product Name : Undisclosed

                          Product Type : Undisclosed

                          Upfront Cash : Undisclosed

                          January 05, 2024

                          Lead Product(s) : Undisclosed

                          Therapeutic Area : Neurology

                          Highest Development Status : Discovery Platform

                          Sponsor : Cajal Neuroscience

                          Deal Size : Undisclosed

                          Deal Type : Collaboration

                          blank

                          03

                          AAPS National Biotech
                          Not Confirmed
                          AAPS National Biotech
                          Not Confirmed

                          Details : The proceeds of financing will support continued optimization of the Creyon Platform, expanding the team, and laying the foundations for a diverse internal pipeline. Creyon’s drug development platform creates purpose-built data sets orders of efficient...

                          Product Name : Undisclosed

                          Product Type : Oligonucleotide

                          Upfront Cash : Undisclosed

                          August 03, 2022

                          Lead Product(s) : Undisclosed

                          Therapeutic Area : Rare Diseases and Disorders

                          Highest Development Status : Discovery

                          Sponsor : DCVC Bio

                          Deal Size : $40.0 million

                          Deal Type : Series A Financing

                          blank